Biotech Values

[Regulardoc]

Dew, thanks for your comprehensive analysis. In Paragraph A, you mention Lovenox's "lower cost." Have you seen anything related to the cost of Xarelto? If used for 35 days psot-op, there may be significant total cost, but I am guessing that the daily dose will be priced much lower than a daily dose of enoxaparin. The pharm companies may have a dilemma on their hands with the pricing. Article the other day on Bloomberg mentioned that the market share for Xarelto for DVT prophylaxis for present indication may be $100 million annually, while if later approved for Afib, the market may approach $2 billion. To compete in the Afib market, they will have to price Xarelto comparable to Pradaxa for a total daily cost, whereas, for the present indication, if they were to price Xarelto near the Pradax cost, they will be leaving "money on the table." If stuck with their present indication for a period of the time, they could actually undercut Lovenox/m-enox by 20% initially, and once they receive an indication for Afib, they could drop the price to compete with Pradaxa.